ArticleJournal of materials science. Materials in medicine2025
Copper tannic acid coordination nanosheet as a potent in-situ antibiotic sustained-release carrier for chronic osteomyelitis.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Antibacterial polyphenols for osteomyelitis treatment: from antibacterial mechanisms to biomaterial-based delivery.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chronic osteomyelitis remains a major challenge in orthopedic therapy. Developing a biodegradable, non-toxic material capable of providing sustained antibiotic release has emerged as a promising approach for localized antibiotic delivery in managing this condition. In this study, copper-tannic acid (CuTA) nanosheets were synthesized and employed as a coating material for vancomycin, resulting in the formation of vancomycin@CuTA (Van@CuTA) nanocomposites. The morphological and structural characterization of CuTA and Van@CuTA was performed using various techniques. The sustained release behavior of vancomycin, and in vitro effects of Van@CuTA on methicillin-resistant Staphylococcus aureus (MRSA) growth, bone marrow mesenchymal stem cells (BMSCs) viability, osteogenesis, and human umbilical vein endothelial cells (HUVECs) angiogenesis were systematically investigated. A rabbit model of chronic osteomyelitis was established to assess the therapeutic effect of Van@CuTA, in combination with fibrin gel, in controlling infection, preventing bone destruction, and inhibiting the progression of chronic osteomyelitis. The characterization results confirmed the formation of Van@CuTA nanocomposites. In vitro experiments revealed that Van@CuTA enabled gradual vancomycin release, effectively suppressed MRSA growth, and demonstrated no toxicity to BMSCs. Furthermore, Van@CuTA significantly promoted osteogenic differentiation of BMSCs and improved angiogenesis in HUVEC. The in vivo studies demonstrated that Van@CuTA coated with fibrin gel ameliorated the appearance of local infection, reduced bone structural damage, and diminished inflammatory infiltration within the bone marrow in the rabbit model of chronic osteomyelitis. Current findings indicated that CuTA nanosheets served as a promising in-situ antibiotic carrier for sustained release in chronic osteomyelitis treatment. Van@CuTA demonstrated improved antibacterial properties, enabled sustained vancomycin release, and promoted both osteogenesis and angiogenesis, leading to its preliminary therapeutic efficacy in rabbit models of chronic osteomyelitis and strong potential for clinical application in osteomyelitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.